KRASmutations can be predictive of resistance to anti-EGFR monoclonal-based therapy in patients with colorectal cancer. Only limited studies, however, have assessed the predictive value ofKRAS mutations in response to conventional chemotherapy. In this Review, the authors assess the available literature and propose that KRASmutations have no value in response prediction to conventional chemotherapy in colorectal cancer, non-small-cell cancer and other solid tumors.
- Yohann Loriot
- Pierre Mordant
- Jean-Charles Soria
